$40.92
2.46% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$41.95
-3.59 7.88% 1M
+12.74 43.62% 6M
+14.13 50.79% YTD
+18.57 79.43% 1Y
+27.01 180.79% 3Y
+22.60 116.80% 5Y
+25.95 162.19% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+3.31 8.57%
ISIN
US00973Y1082
Symbol
AKRO

Key metrics

Market capitalization $3.34b
Enterprise Value $2.63b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-285.42m
Free Cash Flow (TTM) Free Cash Flow $-230.11m
Cash position $743.08m
EPS (TTM) EPS $-3.75
P/E forward negative
Short interest 6.70%
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Akero Therapeutics Inc forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
100%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
86% 86%
-
-0.02 -0.02
86% 86%
-
- Selling and Administrative Expenses 38 38
23% 23%
-
- Research and Development Expense 248 248
75% 75%
-
-285 -285
65% 65%
-
- Depreciation and Amortization 0.02 0.02
86% 86%
-
EBIT (Operating Income) EBIT -285 -285
65% 65%
-
Net Profit -252 -252
66% 66%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Negative
24/7 Wall Street
one day ago
After struggling through a rough patch, the biotech industry seems to be staging a comeback.
Positive
MarketBeat
about one month ago
Mid-cap stocks don't get the same headlines as large caps but move aggressively in both directions, creating outsized opportunities for investors. Unlike their mega-cap counterparts, which tend to grind higher or lower over time, mid-caps often soar or crash within days, driven by headlines, sentiment, and pure speculation.
Neutral
GlobeNewsWire
about one month ago
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH -- -- Presented New Analyses of Week 96 Phase 2b HARMONY in Pa...
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 63
Founded 2017
Website www.akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today